{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:00:33Z","timestamp":1793948433847,"version":"4.8.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-06874-1","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T17:19:19Z","timestamp":1751390359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Metabolic dysfunction-associated fatty liver disease (MAFLD) in the adult population attending a health check-up program in Thailand: prevalence and fibrosis status"],"prefix":"10.1038","volume":"15","author":[{"given":"Supinya","family":"Sono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apichat","family":"Kaewdech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chutimon","family":"Wongsawanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thatchaphon","family":"Varanuntakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Jarupanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichakan","family":"Sritanabutr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papontee","family":"Ruangtanthawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monchusa","family":"Phanukasemsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipikar","family":"Inchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naichaya","family":"Chamroonkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimsiri","family":"Sripongpun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"6","key":"6874_CR1","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol. Int. 14 (6), 889\u2013919 (2020).","journal-title":"Hepatol. Int."},{"issue":"4","key":"6874_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J. Hepatol. 69 (4), 896\u2013904 (2018).","journal-title":"J. Hepatol."},{"issue":"1","key":"6874_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/hep4.1606","volume":"5","author":"VL Chen","year":"2021","unstructured":"Chen, V. L. et al. Effects of cirrhosis and diagnosis scenario in metabolic-associated fatty liver disease\u2010related hepatocellular carcinoma. Hepatol. Commun. 5 (1), 122\u2013132 (2021).","journal-title":"Hepatol. Commun."},{"key":"6874_CR4","doi-asserted-by":"publisher","first-page":"204201882412525","DOI":"10.1177\/20420188241252543","volume":"15","author":"Z Pan","year":"2024","unstructured":"Pan, Z. et al. MAFLD: An ideal framework for understanding disease phenotype in individuals of normal weight. Ther. Adv. Endocrinol. Metab. 15, 20420188241252543 (2024).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"1","key":"6874_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 73 (1), 202\u2013209 (2020).","journal-title":"J. Hepatol."},{"issue":"1","key":"6874_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12876-021-01782-w","volume":"21","author":"YL Chen","year":"2021","unstructured":"Chen, Y. L. et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in china: A cross-sectional comparative study. BMC Gastroenterol. 21 (1), 212 (2021).","journal-title":"BMC Gastroenterol."},{"key":"6874_CR7","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2147\/DMSO.S407657","volume":"16","author":"D Zhang","year":"2023","unstructured":"Zhang, D. et al. Prevalence and risk factors of metabolic-associated fatty liver disease among hospital staff. Diabetes Metab. Syndr. Obes. 16, 1221\u20131234 (2023).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"6874_CR8","doi-asserted-by":"publisher","first-page":"1007171","DOI":"10.3389\/fendo.2022.1007171","volume":"13","author":"F Lei","year":"2022","unstructured":"Lei, F. et al. The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China. Front. Endocrinol. (Lausanne). 13, 1007171 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"5","key":"6874_CR9","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3390\/nu15051123","volume":"15","author":"T Tsutsumi","year":"2023","unstructured":"Tsutsumi, T. et al. The inter-organ crosstalk reveals an inevitable link between MAFLD and extrahepatic diseases. Nutrients 15 (5),  (2023).","journal-title":"Nutrients"},{"issue":"11","key":"6874_CR10","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/s00535-021-01828-6","volume":"56","author":"M Yoneda","year":"2021","unstructured":"Yoneda, M. et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: A retrospective nationwide claims database study in Japan. J. Gastroenterol. 56 (11), 1022\u20131032 (2021).","journal-title":"J. Gastroenterol."},{"issue":"1","key":"6874_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12933-022-01697-0","volume":"21","author":"XD Zhou","year":"2022","unstructured":"Zhou, X. D. et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc. Diabetol. 21 (1), 270 (2022).","journal-title":"Cardiovasc. Diabetol."},{"issue":"3","key":"6874_CR12","doi-asserted-by":"publisher","first-page":"386","DOI":"10.21037\/hbsn-22-421","volume":"12","author":"DQ Sun","year":"2023","unstructured":"Sun, D. Q. et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Hepatobiliary Surg. Nutr. 12 (3), 386\u2013403 (2023).","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"10","key":"6874_CR13","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","volume":"19","author":"VH Nguyen","year":"2021","unstructured":"Nguyen, V. H., Le, M. H., Cheung, R. C. & Nguyen, M. H. Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD. Clin. Gastroenterol. Hepatol. 19 (10), 2172\u201381e6 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"10","key":"6874_CR14","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1007\/s10620-022-07508-6","volume":"67","author":"H Kim","year":"2022","unstructured":"Kim, H. et al. MAFLD predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check-ups. Dig. Dis. Sci. 67 (10), 4919\u20134928 (2022).","journal-title":"Dig. Dis. Sci."},{"key":"6874_CR15","doi-asserted-by":"publisher","first-page":"693507","DOI":"10.3389\/fmed.2021.693507","volume":"8","author":"Q Huang","year":"2021","unstructured":"Huang, Q., Zou, X., Wen, X., Zhou, X. & Ji, L. NAFLD or MAFLD: Which has closer association with all-cause and cause-specific mortality?-Results from NHANES III. Front. Med. (Lausanne). 8, 693507 (2021).","journal-title":"Front. Med. (Lausanne)"},{"key":"6874_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-023-10543-8","volume":"17","author":"XD Zhou","year":"2023","unstructured":"Zhou, X. D. et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol. Int. 17, 1\u201319. (2023).","journal-title":"Hepatol. Int."},{"issue":"5","key":"6874_CR17","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s12072-023-10568-z","volume":"17","author":"K Vaz","year":"2023","unstructured":"Vaz, K. et al. Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes. Hepatol. Int. 17 (5), 1082\u20131097 (2023).","journal-title":"Hepatol. Int."},{"issue":"3","key":"6874_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.cgh.2021.11.038","volume":"21","author":"GEH Lim","year":"2023","unstructured":"Lim, G. E. H. et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin. Gastroenterol. Hepatol. 21 (3), 619\u201329e7 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"6874_CR19","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43 (6), 1317\u20131325 (2006).","journal-title":"Hepatology"},{"issue":"10","key":"6874_CR20","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah, A. G. et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 7 (10), 1104\u20131112 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"4","key":"6874_CR21","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.3390\/ijerph19042096","volume":"19","author":"Q Yuan","year":"2022","unstructured":"Yuan, Q. et al. Prevalence and risk factors of metabolic-associated fatty liver disease among 73,566 individuals in Beijing, China. Int. J. Environ. Res. Public. Health 19 (4), 2096 (2022).","journal-title":"Int. J. Environ. Res. Public. Health"},{"issue":"1","key":"6874_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang, Y. et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: A 4.6-Year cohort study in China. J. Clin. Endocrinol. Metab. 107 (1), 88\u201397 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"6874_CR23","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","volume":"107","author":"KE Chan","year":"2022","unstructured":"Chan, K. E. et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: A meta-analysis and systematic review of 10 739 607 individuals. J. Clin. Endocrinol. Metab. 107 (9), 2691\u20132700 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"6874_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4103\/sjg.SJG_122_18","volume":"24","author":"K Alswat","year":"2018","unstructured":"Alswat, K. et al. Nonalcoholic fatty liver disease burden - Saudi Arabia and united Arab emirates, 2017\u20132030. Saudi J. Gastroenterol. 24 (4), 211\u2013219 (2018).","journal-title":"Saudi J. Gastroenterol."},{"issue":"4","key":"6874_CR25","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/hep.32774","volume":"77","author":"TC Yip","year":"2023","unstructured":"Yip, T. C. et al. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology 77 (4), 1404\u20131427 (2023).","journal-title":"Hepatology"},{"issue":"11","key":"6874_CR26","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/hepr.13821","volume":"52","author":"Y Nagaoki","year":"2022","unstructured":"Nagaoki, Y. et al. Prevalence of fatty liver and advanced fibrosis by ultrasonography and fibroscan in a general population random sample. Hepatol. Res. 52 (11), 908\u2013918 (2022).","journal-title":"Hepatol. Res."},{"key":"6874_CR27","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.cgh.2024.08.020","volume":"23","author":"M Zamani","year":"2024","unstructured":"Zamani, M. et al. Global prevalence of advanced liver fibrosis and cirrhosis in the general population: A systematic review and Meta-analysis. Clin. Gastroenterol. Hepatol. 23, 1123  (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"9","key":"6874_CR28","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.cgh.2017.02.031","volume":"15","author":"SE Mahady","year":"2017","unstructured":"Mahady, S. E. et al. Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis. Clin. Gastroenterol. Hepatol. 15 (9), 1453\u201360e1 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"6874_CR29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","volume":"68","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez, E. & Chalasani, N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J. Hepatol. 68 (2), 305\u2013315 (2018).","journal-title":"J. Hepatol."},{"issue":"4","key":"6874_CR30","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo, P. et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (4), 846\u2013854 (2007).","journal-title":"Hepatology"},{"issue":"15","key":"6874_CR31","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3748\/wjg.v28.i15.1563","volume":"28","author":"T Prasoppokakorn","year":"2022","unstructured":"Prasoppokakorn, T. et al. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease. World J. Gastroenterol. 28 (15), 1563\u20131573 (2022).","journal-title":"World J. Gastroenterol."},{"issue":"10","key":"6874_CR32","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/gut.2007.146019","volume":"57","author":"SA Harrison","year":"2008","unstructured":"Harrison, S. A., Oliver, D., Arnold, H. L., Gogia, S. & Neuschwander-Tetri, B. A. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57 (10), 1441\u20131447 (2008).","journal-title":"Gut"},{"issue":"1","key":"6874_CR33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/hep.32545","volume":"77","author":"P Sripongpun","year":"2023","unstructured":"Sripongpun, P. et al. The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care. Hepatology 77 (1), 256\u2013267 (2023).","journal-title":"Hepatology"},{"issue":"1","key":"6874_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/liv.15718","volume":"44","author":"G Li","year":"2024","unstructured":"Li, G. et al. Diagnostic and prognostic performance of the SAFE score in non-alcoholic fatty liver disease. Liver Int. 44 (1), 15\u201326 (2024).","journal-title":"Liver Int."},{"key":"6874_CR35","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.cgh.2024.06.003","volume":"22","author":"A Kaewdech","year":"2024","unstructured":"Kaewdech, A. et al. Sequential SAFE score and transient elastography for detecting significant fibrosis in Asian patients with MASLD. Clin. Gastroenterol. Hepatol. 22, 2535 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"6874_CR36","doi-asserted-by":"publisher","first-page":"637652","DOI":"10.3389\/fmed.2021.637652","volume":"8","author":"C Sang","year":"2021","unstructured":"Sang, C. et al. Diagnosis of fibrosis using blood markers and logistic regression in Southeast Asian patients with non-alcoholic fatty liver disease. Front. Med. (Lausanne). 8, 637652 (2021).","journal-title":"Front. Med. (Lausanne)"},{"issue":"4","key":"6874_CR37","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/hep.26156","volume":"57","author":"D Kim","year":"2013","unstructured":"Kim, D., Kim, W. R., Kim, H. J. & Therneau, T. M. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the united States. Hepatology 57 (4), 1357\u20131365 (2013).","journal-title":"Hepatology"},{"key":"6874_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.atherosclerosis.2020.03.010","volume":"299","author":"Q Chen","year":"2020","unstructured":"Chen, Q. et al. Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease. Atherosclerosis 299, 45\u201352 (2020).","journal-title":"Atherosclerosis"},{"issue":"4","key":"6874_CR39","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/MEG.0000000000001045","volume":"30","author":"K Wijarnpreecha","year":"2018","unstructured":"Wijarnpreecha, K., Thongprayoon, C., Scribani, M., Ungprasert, P. & Cheungpasitporn, W. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA. Eur. J. Gastroenterol. Hepatol. 30 (4), 404\u2013410 (2018).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"2","key":"6874_CR40","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s12072-015-9690-5","volume":"10","author":"HW Xu","year":"2016","unstructured":"Xu, H. W., Hsu, Y. C., Chang, C. H., Wei, K. L. & Lin, C. L. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease. Hepatol. Int. 10 (2), 340\u2013346 (2016).","journal-title":"Hepatol. Int."},{"issue":"20","key":"6874_CR41","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American heart association. Circulation 148 (20), 1636\u20131664 (2023).","journal-title":"Circulation"},{"issue":"1","key":"6874_CR42","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/hep.32163","volume":"75","author":"P Gin\u00e8s","year":"2022","unstructured":"Gin\u00e8s, P. et al. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology 75 (1), 219\u2013228 (2022).","journal-title":"Hepatology"},{"issue":"9","key":"6874_CR43","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","volume":"17","author":"MS Siddiqui","year":"2019","unstructured":"Siddiqui, M. S. et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin. Gastroenterol. Hepatol. 17 (9), 1877\u201385e5 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"6874_CR44","doi-asserted-by":"publisher","first-page":"254","DOI":"10.14309\/ajg.0000000000001054","volume":"116","author":"ZM Younossi","year":"2021","unstructured":"Younossi, Z. M. et al. Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: Expert panel recommendations. Off. J. Am. Coll. Gastroenterol. ACG 116 (2), 254 (2021).","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"issue":"4","key":"6874_CR45","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","volume":"17","author":"X-D Zhou","year":"2023","unstructured":"Zhou, X-D. et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hep. Intl. 17 (4), 773\u2013791 (2023).","journal-title":"Hep. Intl."},{"issue":"6","key":"6874_CR46","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78 (6), 1966\u20131986 (2023).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06874-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06874-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06874-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T18:10:41Z","timestamp":1751393441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06874-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6874"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06874-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Office of the Human Research Ethics Committee (HREC), Faculty of Medicine, Prince of Songkla University (REC 66-438-9-1), and carried out following the principles and standards outlined in the Declaration of Helsinki and Good Clinical Practice guidelines. As the data were retrospectively retrieved, informed consent of the patients was waived under the HREC approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"21429"}}